Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


15 Items
Title  Creator  Group name  Publishing year 
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study François-Martin et al. EquipeELC 2023-02-13
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer Delaloge et al. EquipePC 2022-05
Real-world evidence of the management and prognosis of young women (?40?years) with de novo metastatic breast cancer Mallet et al. EquipeELC 2022
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population De Laurentiis et al. EquipeCTCS 2022-01
Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France de Calbiac et al. EquipePC 2022-09-01
Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program Bertho et al. EquipePC 2021
Impact of body mass index on overall survival in patients with metastatic breast cancer Saleh et al. EquipePC 2021-02
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population De Laurentiis et al. EquipeCTCS 2021-10
[COVID-19 and people followed for breast cancer: French guidelines for clinical practice of Nice-St Paul de Vence, in collaboration with the Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), the Société d'Imagerie de la Femme (SIFEM), the Société Française de Chirurgie Oncologique (SFCO), the Société Française de Sénologie et Pathologie Mammaire (SFSPM) and the French Breast Cancer Intergroup-UNICANCER (UCBG)] Gligorov et al. EquipeCTCS 2020-05
Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort Pasquier et al. EquipeCTCS Jan 2020
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort Frank et al. EquipePC Aug 2020
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program Jacot et al. EquipeCTCS May 14, 2019
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort Darlix et al. EquipeCTCS Dec 2019
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial Jacot et al. EquipeCTCS 11 14, 2019
Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial Rouzier et al. EquipeCTCS 01 2017
15 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés